Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

CYTX - Cytori Therapeutics Inc.

Previous close
0.2077
0.208   100.000%

Share volume: 0
Last Updated: Fri 26 Jul 2019 10:00:00 PM CEST
Biotechnology: -0.86%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
10%
Profitability 6%
Dept financing 39%
Liquidity 4%
Performance 8%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$0.21
P/E Ratio 
N/A
DAY RANGE
$0.21 - $0.21
EPS 
-$1.48
52 WEEK RANGE
$0.20 - $0.75
52 WEEK CHANGE
-$71.11
MARKET CAP 
4.602 M
YIELD 
N/A
SHARES OUTSTANDING 
22.156 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$21,627,026
AVERAGE 10 VOLUME 
$700,032
AVERAGE 30 VOLUME 
$728,211
Company detail
CEO: Marc H. Hedrick
Region: US
Website: http://www.cytori.com
Employees: 37
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Biotechnology
Sector: Health Technology

Cytori Therapeutics, Inc. is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in San Diego, CA.

Recent news